pegylated irinotecan (SSS22) / 3SBio, JenKem Technology - LARVOL DELTA

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (ChiCTR) - P3 | N=394 | Not yet recruiting | Sponsor: Jilin Cancer Hospital; Jilin Cancer Hospital

New P3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: JenKem Technology Co., Ltd.

New P2 trial • Brain Cancer • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: JenKem Technology Co., Ltd.

New P2 trial • Surgery • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer. (PubMed, Cancer Med) - "JK1201I exhibits promising efficacy and relatively low toxicities as a second-line monotherapy for SCLC, warranting further large-scale clinical studies to evaluate its efficacy in greater detail."

Journal • Monotherapy • P1/2 data • Hematological Disorders • Leukopenia • Lung Cancer • Neutropenia • Oncology • Small Cell Lung Cancer • Solid Tumor

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=394 | Not yet recruiting | Sponsor: JenKem Technology Co., Ltd.

New P3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug. (PubMed, Acta Pharm Sin B) - "In summary, PEG-[Irinotecan] displays superior pharmacokinetic characteristics and antitumor activity with lower toxicity than irinotecan. This supports the view that PEG-[Irinotecan] is a superior anticancer drug to irinotecan and it has entered the phase II trial stage."

Journal • PK/PD data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

"📚 Estamos encantadas y agradecidas de haber participado en esta 6ª Edición de la Summer School Spanish Edition organizada por @eurordis y la @plataformamm Un curso imprescindible para que los pacientes seamos interlocutores formados. 👌🏻 #SSSE22 #PatientAdvocate #EhlersDanlos" (@ANSEDH)

Clinical

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC (clinicaltrials.gov) - P1/2; N=63; Recruiting; Sponsor: JenKem Technology Co., Ltd.

Clinical • New P1/2 trial • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • MRI

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor (clinicaltrials.gov) - P1; N=25; Completed; Sponsor: JenKem Technology Co., Ltd.; Recruiting ➔ Completed; N=40 ➔ 25; Trial primary completion date: Dec 2020 ➔ Mar 2021

Clinical • Enrollment change • Trial completion • Trial primary completion date • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • MRI

[VIRTUAL] Stapled End-to-side Ileocolostomy Provides An Alternative To Conventional Anastomoses And May Outperform Traditional Techniques In Crohn's Disease Of The Terminal Ileum (ACS-CLINCON 2021) - " A total of 67 patients were included(SSS=22, SES=32, HEE=13)... Stapled, end-to-side ileocolostomy for CD is associated with shorter length of stay, lower rate of major complications, and lower recurrence rates compared to side-to-side or end-to-end anastomoses. This is a safe, and technically feasible alternative to the Kono-S which appears to decrease recurrence rates."

Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: JenKem Technology Co., Ltd.

Clinical • New P1 trial • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Neutropenia • Oncology • Pancreatic Cancer • Solid Tumor